Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of Covid-19 infection among those who have been exposed to the virus.
The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop the first antiviral pill for Covid-19.
Pfizer said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic Covid-19 infection.
The trial would test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Merck and partner Ridgeback Biotherapeutics said earlier this month they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of Covid-19 infection.
Pfizer had also said earlier this month it started a mid-to-late-stage trial of PF-07321332 for the treatment of Covid-19 in non-hospitalized, symptomatic adult patients.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Halyna remembered as police probe Baldwin shooting
Colombia’s most-wanted drug lord captured
Mexico hunts for missing children of ‘Dirty War’
Fire blazes cargo ship containers off British Columbia
Former athletics world medallist Quinonez shot dead
Colombia's most-wanted drug lord 'Otoniel' captured
Obama stumps for Virginia candidate in race seen as referendum on Biden
Inquiry into Baldwin shooting focuses on custody of gun
Biden delays release of JFK assassination files